WO2008093881A1 - ニトロキシルラジカルの合成法 - Google Patents
ニトロキシルラジカルの合成法 Download PDFInfo
- Publication number
- WO2008093881A1 WO2008093881A1 PCT/JP2008/051899 JP2008051899W WO2008093881A1 WO 2008093881 A1 WO2008093881 A1 WO 2008093881A1 JP 2008051899 W JP2008051899 W JP 2008051899W WO 2008093881 A1 WO2008093881 A1 WO 2008093881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- atom
- alkyl
- interrupted
- piperidone
- Prior art date
Links
- YLFIGGHWWPSIEG-UHFFFAOYSA-N aminoxyl Chemical compound [O]N YLFIGGHWWPSIEG-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims description 35
- 230000015572 biosynthetic process Effects 0.000 title description 18
- 238000003786 synthesis reaction Methods 0.000 title description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- JWUXJYZVKZKLTJ-UHFFFAOYSA-N Triacetonamine Chemical class CC1(C)CC(=O)CC(C)(C)N1 JWUXJYZVKZKLTJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000003863 ammonium salts Chemical class 0.000 claims abstract description 20
- 150000002576 ketones Chemical class 0.000 claims abstract description 14
- 150000001299 aldehydes Chemical class 0.000 claims abstract description 13
- 150000002829 nitrogen Chemical class 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 86
- 125000001424 substituent group Chemical group 0.000 claims description 56
- 229910052757 nitrogen Inorganic materials 0.000 claims description 50
- 229910052717 sulfur Inorganic materials 0.000 claims description 50
- 125000004434 sulfur atom Chemical group 0.000 claims description 50
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 49
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 45
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 40
- 229920006395 saturated elastomer Polymers 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000002950 monocyclic group Chemical group 0.000 claims description 23
- 125000003367 polycyclic group Chemical group 0.000 claims description 23
- 125000003342 alkenyl group Chemical group 0.000 claims description 22
- 125000000304 alkynyl group Chemical group 0.000 claims description 20
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical class O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 230000001590 oxidative effect Effects 0.000 claims description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000002904 solvent Substances 0.000 description 24
- 150000003254 radicals Chemical class 0.000 description 23
- -1 nitroxyl radicals Chemical class 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000002844 melting Methods 0.000 description 16
- 230000008018 melting Effects 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- 230000009257 reactivity Effects 0.000 description 14
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 125000003003 spiro group Chemical group 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 235000010323 ascorbic acid Nutrition 0.000 description 9
- 229960005070 ascorbic acid Drugs 0.000 description 9
- 239000011668 ascorbic acid Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 9
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 125000002877 alkyl aryl group Chemical group 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KDISMIMTGUMORD-UHFFFAOYSA-N N-acetylpiperidine Natural products CC(=O)N1CCCCC1 KDISMIMTGUMORD-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- 238000007348 radical reaction Methods 0.000 description 4
- YWGKUXPBHOGUBE-UHFFFAOYSA-N 1-[(2,6,6-trimethylcyclohexa-2,4-dien-1-yl)methoxymethyl]piperidin-4-one Chemical compound CC1(C(COCN2CCC(CC2)=O)C(=CC=C1)C)C YWGKUXPBHOGUBE-UHFFFAOYSA-N 0.000 description 3
- HFFPAGMBINLHLT-UHFFFAOYSA-N 2,6-ditert-butylpiperidin-4-one Chemical compound CC(C)(C)C1CC(=O)CC(C(C)(C)C)N1 HFFPAGMBINLHLT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- PIFBMJMXJMZZRG-UHFFFAOYSA-N 2,2,4,6,6-pentamethyl-1,5-dihydropyrimidine Chemical compound CC1=NC(C)(C)NC(C)(C)C1 PIFBMJMXJMZZRG-UHFFFAOYSA-N 0.000 description 2
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Chemical group 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- RPDUDBYMNGAHEM-UHFFFAOYSA-N PROXYL Chemical class CC1(C)CCC(C)(C)N1[O] RPDUDBYMNGAHEM-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- PHENPABYBHPABM-UHFFFAOYSA-N acetic acid;octane Chemical compound CC(O)=O.CCCCCCCC PHENPABYBHPABM-UHFFFAOYSA-N 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000002168 ethanoic acid esters Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229930195733 hydrocarbon Chemical group 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 239000010446 mirabilite Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000012985 polymerization agent Substances 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 1
- 125000006546 (C4-C10) cycloalkyl group Chemical group 0.000 description 1
- YLRRFARMTNWZKA-UHFFFAOYSA-N 1,2-dimethylpiperidin-4-one Chemical compound CC1CC(=O)CCN1C YLRRFARMTNWZKA-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- YHMRKVGUSQWDGZ-UHFFFAOYSA-N 1-phenylmethoxypropan-2-one Chemical compound CC(=O)COCC1=CC=CC=C1 YHMRKVGUSQWDGZ-UHFFFAOYSA-N 0.000 description 1
- NKPMJJGLSFUOPK-UHFFFAOYSA-N 1-tert-butylpiperidin-4-one Chemical compound CC(C)(C)N1CCC(=O)CC1 NKPMJJGLSFUOPK-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- FMRWQLAJBBKXDM-UHFFFAOYSA-N 2,2,5,5-tetramethylpyrrolidine Chemical compound CC1(C)CCC(C)(C)N1 FMRWQLAJBBKXDM-UHFFFAOYSA-N 0.000 description 1
- 125000005810 2,5-xylyl group Chemical group [H]C1=C([H])C(=C(*)C([H])=C1C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VJQKUWBGRBVBMO-UHFFFAOYSA-N 2,6-dimethyl-2,6-bis(phenylmethoxymethyl)piperidin-4-one Chemical compound C1C(=O)CC(C)(COCC=2C=CC=CC=2)NC1(C)COCC1=CC=CC=C1 VJQKUWBGRBVBMO-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 1
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 1
- CUXOKMWBQYZXJS-UHFFFAOYSA-N 6-tert-butyl-2,2-dimethylpiperidin-4-one Chemical compound CC(C)(C)C1CC(=O)CC(C)(C)N1 CUXOKMWBQYZXJS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- 101100274581 Caenorhabditis elegans chc-1 gene Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- PQGAHNJECSVDEI-UHFFFAOYSA-N [CH2]CCCCC Chemical class [CH2]CCCCC PQGAHNJECSVDEI-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BIGPRXCJEDHCLP-UHFFFAOYSA-N ammonium bisulfate Chemical compound [NH4+].OS([O-])(=O)=O BIGPRXCJEDHCLP-UHFFFAOYSA-N 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- YCNIBOIOWCTRCL-UHFFFAOYSA-N azane;2,2,2-trifluoroacetic acid Chemical compound [NH4+].[O-]C(=O)C(F)(F)F YCNIBOIOWCTRCL-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- AOGQPLXWSUTHQB-UHFFFAOYSA-N hexyl acetate Chemical compound CCCCCCOC(C)=O AOGQPLXWSUTHQB-UHFFFAOYSA-N 0.000 description 1
- MWSPFHZPVVWJCO-UHFFFAOYSA-M hydron;methyl(trioctyl)azanium;sulfate Chemical compound OS([O-])(=O)=O.CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC MWSPFHZPVVWJCO-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical class OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000004346 phenylpentyl group Chemical group C1(=CC=CC=C1)CCCCC* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- OVRJVKCZJCNSOW-UHFFFAOYSA-N thian-4-one Chemical compound O=C1CCSCC1 OVRJVKCZJCNSOW-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/20—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations containing free radicals, e.g. trityl radical for overhauser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
Definitions
- the present invention relates to a method for producing a nitroxyl radical derivative, particularly a nitroxyl radical derivative having a substituent at the 2,6-position of a TEMPO compound.
- Nitroxyl radical is a substance with unpaired electrons.
- nitroxyl radicals are highly sensitive to free radicals such as active oxygen, and their distribution in vivo differs depending on their basic structure and the type of substituents. It can also be used as a contrast agent to track free radical reactions.
- the present inventors have focused on this point and have already shown that new in vivo image analysis is performed by using a simultaneous separation imaging method using 14 N and 15 N labeled compounds ( H. Utsumi, K. Yamada, K. Ichikawa, K. Sakai, Y. Kinoshita, S. Matsumoto and M. Nagai, PNAS, 103, 1463 (2006)).
- nitroxyl radicals are generally synthesized from acetone and ammonia (or ammonium chloride).
- Typical nitroxyl radicals obtained by this method include 2, 2, 6, 6-tetramethylbiperidine mono-N-oxyl (TEMPO) derivatives or 2, 2, 5, 5-tetramethylpyrrolidine mono-N-oxyl. (PROXYL) derivatives.
- the present invention relates to a method for producing a 2,6-substituted-4-piperidone derivative shown below, a method for producing a nitroxyl radical derivative using a compound obtained by the method, and a compound obtained by these methods. Etc. are provided.
- R 1 R 2 , R 3 and R 4 are each independently a hydrogen atom, ⁇ Ji ⁇ alkyl group, C 2 C 2 .
- An alkyl group provided that the group may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom, and any one of RR 2 , R 3, and R 4 is a group other than a hydrogen atom, and R 1 and R 2, ⁇ beauty / or, R 3 ⁇ Pi R 4 are each crosslinked to each other, but it may also have a substituent group C 4 C 4.
- a monocyclic or polycyclic saturated ring may be formed, and the saturated ring may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom.
- R is a hydrogen atom or a Ci Ce alkyl group
- R ′ is independently a C 1 C 6 alkyl group.
- R 5 and R 6 are each independently a hydrogen atom, Ci Cs. Alkyl group, C 2 ⁇ C 2. Alkenyl group, C 2 ⁇ C 2. Alkynyl group, C 4 ⁇ C 2. Alkyl Jefferies two Le group, C 6 -C 18 Ariru group, C 6 ⁇ C 2. Alkyl ⁇ aryl group, C 6 ⁇ C 2. Arylalkyl groups, C 4 -C 2 . Chick mouth alkyl group, C 4 -C 2 . A cycloalkenyl group, (Cg Ci. Cycloalkyl) Ci Ci.
- An alkyl group provided that the group may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom, and either one of R 5 and R 6 is a group other than a hydrogen atom, and 15 and 16 May crosslink with each other and may have a substituent.
- C 4 to C 4 The monocyclic or polycyclic saturated ring may be formed, and the saturated ring may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom.
- R 1, R 2 ′, R 3 ′ and R 4 ′ are each independently a hydrogen atom, Ci to C 2 .
- an alkyl group may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom, and any one of R 1, R 2 ′, R 3 ′, and R 4 ′ is a group other than a hydrogen atom, and R 1 ′ and R 2 ′ and / or R 3 ′ and R 4 ′ may be bridged with each other and may have a substituent, and are interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom. May form a C 4 to C 40 monocyclic or polycyclic saturated ring (provided that R 1 ′ and R 2 ′, R 3 ′ and R 4 ′ Except when forming). 2,6-substituted 1-4-piperidone derivatives represented by
- C and C may each independently have a substituent, and may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom.
- C 4 to c 2 A cycloalkylene group, a carbonyl group, a acetoamide group, a sulfonyl group, a sulfonyl group, an oxygen atom or a sulfur atom.
- R 1 R 2 , R 3 and R 4 are each independently a hydrogen atom, An alkyl group, C 2 -C 2 ; Alkenyl group, C 2 ⁇ C 2. Alkynyl group, C 4 -C 20 alkyl gel group, C 6 -C 18 aryl group, C 6 -C 2 . Alkyl ⁇ aryl group, C 6 ⁇ C 2. Arylalkyl group, C 4 -C 2 . Cycloalkyl group, C 4 ⁇ C 2. A cycloalkenyl group, (Cg C. Cycloalkyl) C Ci.
- An alkyl group provided that the group may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom, and any one of RR 2 , R 3, and R 4 is a group other than a hydrogen atom; R 1, R 2 , and Z or R 3 and R 4 may be mutually cross-linked and may have a substituent.
- C 4 to C 4 A monocyclic or polycyclic saturated ring may be formed, and the saturated ring may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom.
- I 1 , R 2 ′, R 3 ′ and R 4 ′ are each independently a hydrogen atom.
- An alkyl group provided that the group may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom, and any one of R, R 2 ′, R 3 ′ and R 4 ′ is other than a hydrogen atom R 1 ′ and R 2 ′, and R or R 3 ′ and R 4 ′ may be mutually bridged and may have a substituent, an oxygen atom, a nitrogen atom, Forms a C 4 to C 40 monocyclic or polycyclic saturated ring optionally interrupted by a sulfur atom (where R 1 ′ and R 2 ′, R 3 ′ and R 4 ′ are substituted, respectively) Except for the case of forming a cyclohexane ring having no group. ]
- X 1 and X 2 may each independently have a substituent, and may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom. C 4 to c 2 .
- the nitroxyl radical derivative according to [1 2] represented by: [14] The following formula:
- a 2,6-substituted 1-4-piperidone derivative can be obtained by a simple method.
- a nitroxyl radical derivative having a substituent at the 2,6-position of a TEMPO compound is obtained by oxidizing the amino group of the obtained 2,6-substituted 4-1 piperidone derivative. It can be obtained in high yield.
- an ammonium salt having a nitrogen nucleus labeled with 15 N is used as a raw material compound.
- the target labeling compound can be easily obtained.
- the obtained nitroxyl radical derivative and its labeled compound are particularly useful as, for example, a contrast medium for tracking free radical reaction in vivo.
- Figure 1 is a graph comparing the reactivity of hydroxyl radicals with three TEMPO-based nitroxyl radical derivatives with different substituents at the 2 and 6 positions.
- Fig. 2 is a graph comparing the reactivity of ascorbic acid with three TEMPO-based nitroxyl radical derivatives with different substituents at the 2,6-positions.
- the method for producing the 2,6-substituted 1-4-piperidone derivative of the present invention has the following formula:
- RR 2 , R 3 and R 4 are each independently a hydrogen atom,.
- An alkyl group, and the group may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom, and any one of I 1 , R 2 , R 3, and R 4 is other than a hydrogen atom Group, and 2 , and Binomatawa, R 3 and R 4 are each crosslinked to each other, but it may also have a substituent group C 4 -C 4.
- a monocyclic or polycyclic saturated ring may be formed, and the saturated ring may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom.
- a 2,6-substituted 4-piperidone derivative represented by the formula:
- R is a hydrogen atom or a C 1 to C 6 alkyl group
- R ′ is independently a C Ce alkyl group.
- R 5 and R 6 are each independently a hydrogen atom, C 1 -C 2 .
- step ⁇ as shown in the following reaction scheme, a triacetonamine derivative (compound represented by formula (1)) is converted to a formula (compound represented by formula (i))
- a 2,6-substituted 14-piperidone derivative represented by the formula (I) can be obtained.
- Y represents a halogen atom, an acetyloxy group, a trifluoroacetyloxy group, Formate (HC0 2 ) or hydrogen sulfate (HS0 4 ).
- the triacetonamine derivative is reacted with the ketone or aldehyde derivative represented by the formula (2) in the presence of ammonium salt by the simple method.
- substituents be introduced at both or at least one of the 6 positions, but the nitrogen nuclei of the substrate can be labeled with 15 N if desired.
- the obtained 2,6-substituted 1-4-piperidone derivative can be easily obtained the target nitroxyl radical derivative or its labeled compound by oxidation according to a conventional method. It is useful as an intermediate compound for labeling compounds. (Raw compound)
- step A The raw material compound used in step A will be described.
- the triacetoneamine derivative used in the present invention has the following formula:
- R is a hydrogen atom or a Ci Ce alkyl group
- R ′ is independently an alkyl group.
- “Completely identical” means not only the type of substituent and bonding position, but also the same, including the three-dimensional structure and the presence or absence of isotopes.
- examples of the Ci to C 6 alkyl group include a methyl group, an ethyl group, a propyl group, an isopropylinole group, an n-butinole group, an s-butinole group, a t-butinole group, a pentinole group, and a hexyl group. It is done.
- R is preferably a hydrogen atom, a methyl group or an ethyl group, and particularly preferably a methyl group.
- R ′ is preferably a methyl group or an ethyl group, and particularly preferably a methyl group.
- triacetoneamine (a compound in which R is a hydrogen atom and R ′ is all a methyl group) or N_methyl monotriacetonamine (R is methyl) And a compound in which R and are all methyl groups) is preferably used in that a commercially available product can be easily obtained.
- R is preferably a methyl group, and N-methyl-triacetoneamine is preferred. Used for These compounds are commercially available from, for example, Aldrich.
- R 5 and R 6 in the formula are each independently a hydrogen atom.
- ⁇ . 2 Alkyl group, C 2 ⁇ C 2.
- Cycloalkyl) C JL C alkyl group provided that the group may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom, and either R 5 or R 6 is a group other than a hydrogen atom.
- R 5 and R 6 may be cross-linked with each other and may have a substituent.
- C 4 to C 4 The monocyclic or polycyclic saturated ring may be formed, and the saturated ring may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom.
- R 5 and R 6 are preferably crosslinked to form a 5- to 8-membered ring.
- the ketone or aldehyde derivative represented by the formula (2) may be used singly or in combination of two or more.
- Alkyl group C 1 ⁇ C 1. It is preferably an alkyl group.
- alkyl group include methyl group, ethyl group, propyl group, isopropyl group, n-butyl group, s-butyl group, t-butyl group, pentyl group, hexyl group, octyl group, nonyl group, decyl group, Examples include undecyl and dodecyl groups.
- Alkenyl group C 2 ⁇ C 1.
- An alkenyl group is preferred.
- Examples of the alkenyl group include a bur group, a allyl group, a propylene group, an isopropyl group, a 2-methyl-1-propenyl group, a 2-methylaryl group, and a 2-butenyl group.
- C 2 -C 20 alkynyl group is preferably a C 2 -C 10 alkynyl group.
- alkynyl group include an ethur group, a propynyl group, and a propyl group.
- Alkyl Jenni Le group C 4 ⁇ Ci. It is preferably an alkyl gel group. Examples of the alkylgenyl group include a 1,3-butagel group.
- the C 6 -C 8 aryl group is Ce Ci.
- An aryl group is preferred. Examples of aryl groups include phenyl, 1-naphthyl, 2-naphthyl, indenyl, biphenyl, anthryl, and phenanthryl groups.
- the alkylaryl group is preferably a C 6 -C 10 alkylaryl group.
- alkylaryl groups include: -Tolyl group, m-tolyl group, Examples include p-tolyl group, 2,3-xylyl group, 2,5-xylyl group, o-tamenyl group, m-tamenyl group, P-tamenyl group, mesityl group and the like.
- the aryl group is Ce Ci.
- An aryl group is preferred.
- Examples of arylalkyl groups include benzyl, phenethyl, 1-naphthinoremethinole, 2-naphthylmethinole, 1-phenyl / retinore, phenylpropyl, phenylbutyl, phenylpentyl, and phenyl.
- -Ruhexyl group methylbenzyl group, dimethylenobenzinole group, trimethinolevenzinole group, ethinolevenzyl group, methylphenethyl group, dimethylphenethyl group, and jetylbenzyl group.
- the cycloalkyl group is preferably a C 4 to C 10 cycloalkyl group.
- Examples of the cycloalkyl group include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, and the like.
- Cycloalkenyl groups C 4 -C.
- a cycloalkenyl group is preferred.
- Examples of the cycloalkenyl group include a cyclopropenyl group, a cyclobutenino group, a cyclopentenino group, a cyclopentagenino group, and a cyclohexenino group.
- alkyl group (C 3 ⁇ C King 0 consequent opening alkyl) C ⁇ . 1.
- the alkyl group include a group composed of a combination of the above-described cycloalkyl group and alkyl group.
- These groups may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom.
- these groups When these groups are interrupted by a nitrogen atom, it is preferably a group represented by 1 N (Z) 1 (wherein Z is a hydrogen atom or a hydrocarbon group).
- Z is a hydrogen atom or a hydrocarbon group.
- preferred examples of the hydrocarbon group include an alkyl group, an alkenyl group, and an alkynyl group.
- these groups are interrupted by a sulfur atom, it is preferably a group represented by 1 S ( ⁇ ) n — (wherein n is 0, 1 or 2).
- examples of the ketone or aldehyde derivative represented by the formula (2) include the following compounds, which are easily available as commercial products.
- R 5 and R 6 are cross-linked to each other, which may have a substituent C 4 -C 4.
- the monocyclic or polycyclic saturated ring may be formed, and the saturated ring may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom.
- the monocyclic or polycyclic saturated ring is preferably a C 4 to c 20 monocyclic or polycyclic saturated ring.
- the scales 5 and 16 are preferably crosslinked to form a 5- to 8-membered ring.
- R 1 and R 2 and / or R 3 and R 4 in formula (I) are the same as R 5 and R 6. , and the respective crosslinked to each other, which may have a substituent C 4 -C 4.
- the saturated ring may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom, but the monocyclic or polycyclic saturated ring is , C 4 ⁇ C 2. It is preferably a monocyclic or polycyclic saturated ring, and more preferably a 5- to 8-membered ring by crosslinking.
- cycloalkyl C 4 ⁇ C 1.
- a cycloalkenyl group (Cg Ci. Cycloalkyl) C 1 -C 1 . Examples thereof include an alkyl group, a carbonyl group, an amino group, and a halogen atom.
- ketone derivatives include the following formula:
- X represents an alkylene group, a carbonyl group, an acetoamide group, a sulfonyl group, a sulfier group, an oxygen atom or a sulfur atom which may have a substituent.
- X represents an alkylene group, a carbonyl group, an acetoamide group, a sulfonyl group, a sulfier group, an oxygen atom or a sulfur atom which may have a substituent.
- alkylene group As a substituent of the alkylene group, ⁇ . . Alkyl group, c 2 to c 10 alkenyl group,. 2. . Alkynyl group, C 4 -C. Alkyl Jenny Le group, C 6 -C 10 ⁇ aryl group, C 6 ⁇ C 1. Alkylaryl group, C 6 -C 1 . Arylalkyl group, C 4 -C. Cycloalkyl group, C 4 ⁇ C i. Cycloalkenyl group, (C 3 ⁇ C 1. Consequent opening alkyl). Examples include an alkyl group.
- the alkylene group is preferably a Ci Cgo alkylene group, CC. More preferred is an alkylene group. Specifically, a methylene group, an ethylene group, a trimethylene group, a propylene group and the like are preferable, and among them, a methylene group is preferable.
- X is an alkylene group which may have a substituent, it has two substituents, and these substituents cross-link each other and have a substituent.
- C 4 to C 2 A monocyclic or polycyclic saturated ring may be formed, and the saturated ring may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom.
- the substituent include the same substituents as R 5 and R 6 .
- the saturated ring is interrupted by a nitrogen atom, it is preferably a group represented by _N (Z) — (wherein Z is a hydrogen atom or Ci Cs. A hydrocarbon group).
- hydrocarbon group examples include an alkyl group, an alkenyl group, and an alkynyl group.
- these groups are interrupted by a sulfur atom, it is preferably a group represented by 1 S (O) n— (wherein n is 0, 1 or 2).
- Examples of the compound represented by the formula (ii) include the following compounds, and these are easily available as commercial products.
- the amount of the ketone or aldehyde derivative represented by the formula (2) is preferably 1.0 to 10.0 equivalent, more preferably 2.0 to 5 with respect to 1 equivalent of the triacetonamine derivative. 0 equivalent, particularly preferably 2.0 to 3.0 equivalent.
- the ammonium salt used in the present invention is not particularly limited, but those capable of allowing the reaction to proceed under relatively mild conditions are preferably used. For example, the following formula:
- Y is a halogen atom, an acetyloxy group, a trifluoroacetyloxy group, a formate (HC0 2 ) or a hydrogen sulfate (HS0 4 ).
- the compound represented by this can be used.
- examples of the halogen atom include fluorine, chlorine, bromine, and silicon, and chlorine or bromine is particularly preferable. More specifically, ammonium chloride salt, ammonium bromide salt, ammonium acetate salt, ammonium trifluoroacetate salt, ammonium formate salt, ammonium hydrogen sulfate salt, etc. are preferably used.
- an ammonium salt with a nitrogen nucleus labeled with 15 N is used.
- a 15 N labeled compound of ammonium salt the resulting 2,6-substituted 14-piperidone derivative can be easily labeled.
- the amount of ammonium salt used is preferably 2.0 to 10.0 equivalents, more preferably 3.0 to 8.0 equivalents, and particularly preferably 5.0 to 7 equivalents per equivalent of the triacetonamine derivative. 0 equivalents.
- step A the reaction is carried out by mixing a raw material compound such as a triacetonamine derivative, a ketone or aldehyde derivative represented by the formula (2), or an ammonium salt in a solvent.
- the reaction solvent is not particularly limited as long as it is inert to these compounds.
- organic solvents such as DMSO, DMF, THF, dioxane, methanol, ethanol and propanol are preferably used.
- the reaction in step A can be performed under relatively mild conditions, and the reaction temperature is preferably room temperature to 90 ° C, more preferably 50 to 80 ° C, and particularly preferably 6 Perform at 0 to 70 ° C.
- the reaction time may be appropriately determined while confirming the progress of the reaction, but is usually about 3 to 20 hours, preferably 5 to 15 hours, more preferably 6 to 10 hours.
- Step A can be performed under pressure, reduced pressure, or atmospheric pressure, but it is desirable to perform it in an atmospheric pressure atmosphere for ease of operation.
- the product can be separated and extracted from the reaction solution by a conventional method and purified to obtain the desired 2,6-substituted -4-piperidone derivative.
- step A substituents can be introduced at the 2- and 6-positions of 4-piperidone by a simple method as described above. For this reason, it is possible to easily obtain 2,6-substituted mono-4-piperidone derivatives having various properties. Moreover, by using the Anmoniumu salt nitrogen nuclei were labeled with 1 5 N, can also be obtained 2, 6 1 5 N-labeled compounds of the monosubstituted 4-Piperi Don derivatives in high yields, prior art methods This has the advantage that the manufacturing process can be simplified.
- R, R 2 ', R 3 ' and R 4 ' are each independently a hydrogen atom.
- C 2 Alkyl group, C 2 ⁇ C 2. Alkenyl group, C 2 ⁇ C 2. Alkynyl group, C 4 -C 20 alkyl Genis Le group, C 6 -C 18 Ariru group, C 6 ⁇ C 2. Alkyl ⁇ aryl group, C 6 ⁇ C 2. Arylalkyl group, C 4 -C 2 . Chick mouth alkyl group, C 4 -C 2 . Sik Roarukeniru group, (C 3 ⁇ C. Cycloalkyl) C i ⁇ C.
- An alkyl group provided that the group may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom, and any one of R 1, R 2 ′, R 3 ′, and R 4 ′ is other than a hydrogen atom.
- R 1 ′ and R 2 ′, and Z or R 3 ′ and R 4 ′ may be mutually bridged and may have a substituent, oxygen atom, nitrogen atom, sulfur atom in which it may be interrupted c 4 ⁇
- X 1 and X 2 may each independently have a substituent, and may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom. C 4 to C 2 .
- X 1 and And X 2 is a limitation of X, and since the substituents and preferred examples are the same as those of X, description thereof will not be repeated here.
- Preferable examples of the 2,6-substituted-4-piperidone derivative obtained by the method of the present invention include the following compounds.
- R 1 R 2 , R 3 and R 4 are each independently a hydrogen atom, Alkyl group, c 2 ⁇ c 2. Anorekeniru group, C 2 ⁇ C 2. Alkynyl group, C 4 ⁇ C 2. ⁇ Rukirujeniru group, C 6 -C 18 Ariru group, C 6 ⁇ C 2. Alkylaryl group, C
- a monocyclic or polycyclic saturated ring may be formed, and the saturated ring may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom.
- the process comprises the step of oxidizing the amino group of a 2,6-substituted 1-4-piperidone derivative represented by the following formula to generate a ditroxyl radical (hereinafter also referred to as “Step B”).
- Step B as shown in the following reaction scheme, the 2,6-substituted 4-piperidone derivative amino acid obtained in Step A of “Method for Producing 2,6-Substituted 1-4-Piperidone Derivative” above is used.
- Nitroxyl radicals can be obtained by oxidizing the group.
- Step B a substituent can be introduced at the 2nd and 6th positions of the TEMPO compound by a simple method.
- the labeled compound of the target nitroxyl radical derivative can be obtained in high yield.
- Examples of the oxidizing agent used in Step B include hydrogen peroxide, perbenzoic acids such as m-cloperbenzoic acid, peracetic acid, periodic acid, and oxonic acid. Among them, it is preferable to use hydrogen peroxide, and it is particularly preferable to use 30% hydrogen peroxide.
- the amount of the oxidizing agent used is preferably 3 to 50 equivalents, more preferably 5 to 15 equivalents, and particularly preferably 7 to 10 equivalents per equivalent of 2,6-substituted mono-4-piperidone.
- an oxidation catalyst may be used in combination. Examples of oxidation catalysts that can be used include sodium tungstate and methyltrioctylammonium hydrogensulfate. The reaction is preferably performed in a solvent.
- the solvent is not particularly limited as long as it is inert to 2,6-substituted 1-4-piperidone derivatives.
- alcohols such as alcohol and methanol
- organic solvents such as chloroform and dichloromethane are preferably used.
- step B Next, the reaction conditions in step B will be described.
- the reaction temperature is preferably 0 to 30 ° C, more preferably 15 to 30 ° C, and particularly preferably 20 to 25 ° C.
- the reaction time may be appropriately determined while confirming the progress of the reaction, but is usually about 10 to 40 hours, preferably 15 to 30 hours, more preferably 20 to 25 hours. It is.
- Step B can be performed under pressure, reduced pressure, or atmospheric pressure, but it is desirable to perform it in an atmospheric pressure atmosphere for ease of operation.
- the product After completion of the reaction, the product can be separated and extracted from the reaction solution by a conventional method and purified to obtain the desired ditoxyl radical derivative.
- a simple method of oxidizing an amino group of a 2,6-substituted mono-4-piperidone derivative has the following formula:
- RR 2 , R 3 and R 4 have the same meaning as described above.
- the ditoxyl radical derivative represented by the formula can be obtained in high yield. Further, the 15 N-labeled compound of the nitroxyl radical derivative can be easily obtained in a high yield by using the 15 N-labeled compound of a 2,6-substituted 14-piperidone derivative.
- the present invention also includes the compound thus obtained.
- R 1 , R 2 , R 3 ′ and R 4 ′ are each independently a hydrogen atom, Ci to C 2 .
- a monocyclic or polycyclic saturated ring (where R 1 ′ and R 2 ′, R 3 ′ and R 4 ′ each form a hexane ring having no substituent) except for. ) .
- the nitroxyl radical derivative represented by these is preferable. These compounds may exhibit different properties from conventional compounds and are expected to be applied in various applications.
- X 1 and X 2 may each independently have a substituent, and may be interrupted by an oxygen atom, a nitrogen atom, or a sulfur atom. C 4 to c 2 . Cycloalkylene group, carbonyl group, acetoamide group, sulfonyl group, sulfinyl group, oxygen atom Or it is a sulfur atom.
- the nitroxyl radical derivative represented by these is mentioned.
- 1 and 2 limit X, and since the substituents and preferred examples are the same as those of X above, description thereof will not be repeated here.
- nitroxy radical derivative obtained by the method of the present invention include the following compounds.
- nitroxyl radical derivative 1 5 New labeling compounds nitrogen nuclei are labeled with 1 5 New are preferably exemplified.
- This nitroxyl radical derivative can be widely used as an antioxidant, a chemical battery, a polymerization agent and the like. In particular, it is useful as a contrast agent for tracking free radical reactions in vivo by utilizing its high sensitivity to free radicals such as active oxygen.
- Nitroxyl radical derivatives administered in vivo differ in distribution in vivo depending on the basic structure and type of substituents.
- Example 1
- Triacetamine 1.55 g (1 eq), NH 4 C 1 3.2 1 g (6 eq) and cyclohexanone 2.94 g (3 eq) in DMSO solvent (20 ml), 6
- the mixture was heated and stirred at 0 ° C for 15 to 20 hours.
- the solution was diluted with water (40 ml), acidified with 7% hydrochloric acid (10 ml), and the neutral part was extracted and removed with ether.
- the mother liquor was adjusted to pH 9-10 using 10% aqueous potassium carbonate solution and extracted three times with ethyl acetate.
- N-methyl-triacetonamine 1.69 g (1 equivalent), NH 4 C 13.21 g (6 equivalents) and cyclohexanone 2.94 g (3 equivalents) in DMSO solvent (20 ml) The mixture was stirred at 60 ° C for 5 hours.
- the reaction solution was diluted with water (40 ml), acidified with 7% hydrochloric acid (10 ml), and the neutral part was extracted and removed with ether.
- the mother liquor was adjusted to pH 9 to 10 using 10% aqueous potassium carbonate solution, and extracted three times with ethyl acetate. The extracted ethyl acetate layers were combined, washed twice with brine, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure.
- the obtained oily substance was purified by silica gel column chromatography (developing solvent; hexane: acetic acid ester), and the obtained crystals were recrystallized from ethyl hexane acetate. As a result, 788 mg of 2,6-spirocyclohexylpiperidin-4-one was obtained (yield 34%).
- Triacetonamine 1.55 g (1 equivalent), NH 4 C 13.21 g (6 equivalents) and 4-oxotetrahydropyran 3.00 g (3 equivalents) in DMSO solvent (10 ml) at 60 ° Stir at C for 15-20 hours.
- the reaction solution was diluted with water (40 ml), acidified with 7% hydrochloric acid (10 ml), and the neutral part was extracted and removed with ether.
- the mother liquor was adjusted to pH 9-10 with 10% aqueous potassium carbonate solution and extracted three times with chloroform.
- the extracted black mouth form layers were combined, washed twice with a saline solution, dried with sodium sulfate, and the solvent was removed.
- the obtained oily substance was purified by silica gel column chromatography (developing solvent; hexane: acetate: methanol), and the obtained crystal was recrystallized from hexane monoacetate. As a result,
- Example 2 in place of the NH 4 C 1, the nitrogen nucleus except for using labeled 15 NH 4 C 1 at 15 N, a reaction was conducted in the same manner as in Example 2. As a result, in Step A, 780 mg of a 15 N-labeled compound of 2,6-spirosic hexylbiperidin-4-one was obtained (yield 34%). Melting point 100. 4 ° C.
- Step B 2,6-spirocyclohexylbiperidine mono-4-one 1-oxyl 43 Omg was obtained (yield 80%). Melting point 1 1 7. 4 ° C.
- Example 3 N-methyl-triacetonamine 1.69 gg (1 equivalent) was used instead of triacetonamine, and NH 4 C 1 was replaced with a nitrogen nucleus labeled with 15 N 15 NH 4 The reaction was performed in the same manner as in Example 3 except that C 1 was used. As a result, in Step A, 760 mg of bis (tetrahydropyran-1,4,1 spiro) -1,6-piperidin-4_one was obtained (yield 32%). Melting point 1 67 ° C.
- step B bis (Tetorahi Doropiran one 4 one spiro) one 2, 6-pin Perijin - 4 one on 1 Okishiru 15 to give the N-labeled compound 1 05 mg (yield: 7 5%).
- step B bis (Tetorahi Doropiran one 4 one spiro) one 2, 6-pin Perijin - 4 one on 1 Okishiru 15 to give the N-labeled compound 1 05 mg (yield: 7 5%).
- Step A of Example 2 Step A of Example 2 was used except that 3.48 g (3 equivalents) of tetrahydrothiopyran-4-one was used instead of cyclohexanone.
- bis (tetrahydrothiopyran-1,4-spiro) _2,6-piperidin-4-one 8 1 3 mg was obtained (yield 30%).
- Step A of Example 2 Same as Step A of Example 2 except that in Step A of Example 2, 4.68 g (3 equivalents) of 1,4-cyclohexandione monoethylene acetal was used instead of cyclohexanone. In this way, bis (1, monoethylenedioxycyclohexane-1,4,1 spiro) 1,2,6-piperidine-1,4,1-one 1. 1 2 g (yield 32%) was obtained. Melting point 1 90. 6 ° C.
- the oily substance was separated by silica gel column chromatography (developing solvent hexane: ethyl acetate), and 2,6-dimethyl-2,6-dibenzyloxymethyl-4-piperidone 41 Omg oily substance (yield) And an oily substance (yield 20%) of 2,2,6-trimethyl-benzyloxymethyl -4-piperidone 512 mg.
- Step A of Example 2 In the same manner as in Step A of Example 2, except that in Step A of Example 2, 2.12 g of N-acetylyl 41-piperidone was used in place of hexanone, 2 ⁇ (N-Acetylbiperidine-1,4,1 spiro)-6,6-Dimethylpiperidine-1,4-one and bis (N-acetylpiperidine-1,4, spiro) —2,6,1 Piperidine I got 4—on.
- the extraction solvent is black mouth form, and the oily substance is separated by silica gel column chromatography (developing solvent 1-5% methanol: CHC 1 3 ), and 2- (N-acetyl piperidine 1,4-spiro) 1,6-Dimethylpiperidin-4-one 556 mg (crystals obtained by recrystallization from hexane monoacetate, melting point 82-83 ° C), and bis (N-acetylbiperidine-1,4- -Spiro) _2, 6-piperidine 4-1one 328 mg (crystals obtained by recrystallization from hexyl monoacetate, mp 165-166 ° C).
- Step A of Example 2 instead of cyclohexanone, 1 7, iS-hydroxy 1 17, ⁇ -methyl 1 5, ⁇ -androstan 1 3_one 2. 25 g were used In the same manner as in Step A of Example 2, except that 2— (17, monohydroxy-1-7 ′ ⁇ -methylolene 5, ⁇ -androstane 3-spiro) -6,6 _dimethylbiperidine 4-one and bis (17, / 3-hydroxy-17, ⁇ -methyl-5, ⁇ -androstane-1, 3-spiro) 1,2,6-piperidine and 4-one were obtained.
- the extraction solvent is black mouth form, and the oily substance is separated by silica gel column chromato (developing solvent: ethyl acetate: hexane), and 2— (17, j3—hydroxy 17, ⁇ -methinole. 1 5, ⁇ -androstane 1 3-spiro 1 6, 6-dimethylbiperidine-4 monoone 1 3 Omg (crystals obtained by recrystallization from toluene, melting point 1 5 6. 7 to 1 5 8.
- nitroxyl radicals have also been reported to react with reducing substances (Couet, WR, Tetrahedron, 41 (7), 1165-1172 (1985), Finkelstein, E “Biochimica et Biophysica Acta, 802, 90- 98 (1984)) Therefore, after mixing a nitroxyl radical (1 0— 5 ⁇ ⁇ ) with ascorbic acid (1 00 ⁇ -2 mM), a certain amount was collected in a capillary and measurement was started. As a result, we examined the reactivity with ascorbic acid, a typical reducing substance in the living body, by observing the decrease in ESR signal intensity over time. Was found to react little with ascorbic acid, while 2,6-dispiro.
- nitroxyl radical derivative obtained by the present invention can be widely used as a contrast agent, an antioxidant, a battery, a polymerization agent and the like in the field of chemical industry.
- nitroxyl radical 15 N-labeled compounds are useful as contrast agents for tracking free radical reactions in vivo.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08710831A EP2128135A4 (en) | 2007-01-31 | 2008-01-30 | PROCESS FOR THE SYNTHESIS OF A NITROXYL RADICAL |
JP2008556217A JP5311472B2 (ja) | 2007-01-31 | 2008-01-30 | ニトロキシルラジカルの合成法 |
US12/523,341 US8513417B2 (en) | 2007-01-31 | 2008-01-30 | Method for synthesis of nitroxyl radical |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-022042 | 2007-01-31 | ||
JP2007022042 | 2007-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008093881A1 true WO2008093881A1 (ja) | 2008-08-07 |
Family
ID=39674180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/051899 WO2008093881A1 (ja) | 2007-01-31 | 2008-01-30 | ニトロキシルラジカルの合成法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8513417B2 (ja) |
EP (1) | EP2128135A4 (ja) |
JP (1) | JP5311472B2 (ja) |
WO (1) | WO2008093881A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009196912A (ja) * | 2008-02-20 | 2009-09-03 | Ihi Corp | 磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置 |
WO2011052759A1 (ja) * | 2009-10-29 | 2011-05-05 | 国立大学法人九州大学 | 新規ニトロキシルラジカル化合物及びその製造方法 |
WO2022196621A1 (ja) * | 2021-03-17 | 2022-09-22 | Tdk株式会社 | 含フッ素化合物および造影剤 |
WO2022196523A1 (ja) * | 2021-03-17 | 2022-09-22 | Tdk株式会社 | 含フッ素化合物および造影剤 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5010281B1 (ja) * | 1970-03-20 | 1975-04-19 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4412414Y1 (ja) | 1966-07-15 | 1969-05-23 | ||
JPS471627Y1 (ja) | 1967-07-24 | 1972-01-20 | ||
JPS4631733Y1 (ja) | 1967-08-25 | 1971-11-02 | ||
JPS5010281Y1 (ja) | 1969-02-15 | 1975-04-01 | ||
EP1629013B1 (en) | 2003-05-31 | 2018-01-24 | Amgen Research (Munich) GmbH | Pharmaceutical composition comprising a bispecific antibody specific for epcam |
JP4631733B2 (ja) | 2006-02-08 | 2011-02-16 | セイコーエプソン株式会社 | 印刷制御装置、印刷制御方法およびプログラム |
JP4412414B2 (ja) | 2007-12-07 | 2010-02-10 | 横浜ゴム株式会社 | 複層ガラスパネルのグレージングガスケット成形方法及び装置 |
-
2008
- 2008-01-30 WO PCT/JP2008/051899 patent/WO2008093881A1/ja active Application Filing
- 2008-01-30 US US12/523,341 patent/US8513417B2/en not_active Expired - Fee Related
- 2008-01-30 JP JP2008556217A patent/JP5311472B2/ja not_active Expired - Fee Related
- 2008-01-30 EP EP08710831A patent/EP2128135A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5010281B1 (ja) * | 1970-03-20 | 1975-04-19 |
Non-Patent Citations (14)
Title |
---|
C. WETTER ET AL., CHEM. EUR. J., vol. 10, 2004, pages 1156 |
COUET, W R., TETRAHEDRON, vol. 41, no. 7, 1985, pages 1165 - 1172 |
FINKELSTEIN, E., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 802, 1984, pages 90 - 98 |
H. UTSUMI ET AL., PNAS, vol. 103, 2006, pages 1463 |
JOCKUSCH S. ET AL.: "Time Resolved CW-EPR Spectroscopy of Powdered Samples: Electron Spin Polarization of a Nitroxyl Radical Adsorbed on NaY Zeolite, Generated by the Quenching of Excited Triplet Ketones", J. PHYS. CHEM. B, vol. 105, no. 31, 2001, pages 7477 - 7481, XP008112468 * |
MA Z. ET AL.: "Oxoammonium salts. 5. A new synthesis of hindered piperidines leading to unsymmetrical TEMPO-type nitroxides. Synthesis and enantioselective oxidations with chiral nitroxides and chiral oxoammonium salts", J. ORG. CHEM., vol. 58, no. 18, 1993, pages 4837 - 4843, XP008112467 * |
MIURA Y. ET AL.: "Living' radical polymerization of styrene mediated by spiro ring-substituted piperidinyl-N-oxyl radicals. The effect of the spiro rings on the control of polymerization", POLYMER, vol. 44, no. 18, 2003, pages 5187 - 5194, XP004441838 * |
MIURA Y. ET AL.: "Low-Temperature "Living" Radical Polymerization of Styrene in the Presence of Nitroxides with Spiro Structures", MACROMOLECULES, vol. 34, no. 3, 2001, pages 447 - 455, XP008112466 * |
See also references of EP2128135A4 |
TAKESHITA ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1573, 2002, pages 156 - 164 |
WETTER C. ET AL.: "Steric and electronic effects in cyclic alkoxyamines - Synthesis and applications as regulators for controlled/living radical polymerization", CHEMISTRY - EUROPEAN JOURNAL, vol. 10, no. 5, 2004, pages 1156 - 1166, XP008112505 * |
WILEN C.-E. ET AL.: "Synthesis of Novel Hindered Amine Light Stabilizers (HALS) and Their Copolymerization with Ethylene or Propylene over Both Soluble and Supported Metallocene Catalyst Systems", MACROMOLECULES, vol. 33, no. 14, 2000, pages 5011 - 5026, XP001065167 * |
Y MIURA; N. NAKAMURA; I. TANIGUCHI, MACROMOLECULES, vol. 34, 2001, pages 447 |
YOSHIOKA T. ET AL.: "Studies on stable free radicals. VIII. The synthesis and oxidation of hindered 4-oxopiperidine derivatives", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 45, no. 2, 1972, pages 636 - 638, XP002493103 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009196912A (ja) * | 2008-02-20 | 2009-09-03 | Ihi Corp | 磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置 |
WO2011052759A1 (ja) * | 2009-10-29 | 2011-05-05 | 国立大学法人九州大学 | 新規ニトロキシルラジカル化合物及びその製造方法 |
JP5911131B2 (ja) * | 2009-10-29 | 2016-05-11 | 国立大学法人九州大学 | 新規ニトロキシルラジカル化合物及びその製造方法 |
WO2022196621A1 (ja) * | 2021-03-17 | 2022-09-22 | Tdk株式会社 | 含フッ素化合物および造影剤 |
WO2022196523A1 (ja) * | 2021-03-17 | 2022-09-22 | Tdk株式会社 | 含フッ素化合物および造影剤 |
Also Published As
Publication number | Publication date |
---|---|
JP5311472B2 (ja) | 2013-10-09 |
US20100076190A1 (en) | 2010-03-25 |
JPWO2008093881A1 (ja) | 2010-05-20 |
EP2128135A4 (en) | 2011-07-06 |
EP2128135A1 (en) | 2009-12-02 |
US8513417B2 (en) | 2013-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3153529A1 (en) | Brd9 bifunctional degraders and their methods of use | |
JP2002514644A (ja) | メタロプロテイナーゼ阻害剤としての置換アリールヒドロキサム酸 | |
EP0157738B1 (de) | Verfahren zur Herstellung von Nitroxylen sterisch gehinderter Amine | |
US10676443B2 (en) | Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile | |
WO2008093881A1 (ja) | ニトロキシルラジカルの合成法 | |
JP2002514647A (ja) | メタロプロテイナーゼ阻害薬としての新規な置換アリールヒドロキサム酸 | |
ES2637744T3 (es) | Proceso para la síntesis industrial de lurasidona | |
FR2803848A1 (fr) | Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2308867C (fr) | Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
Singhal et al. | Facile One-Pot Friedlander Synthesis of Functionalized Quinolines using Graphene Oxide Carbocatalyst | |
US2587262A (en) | Chs chzghjoh | |
Wang et al. | A clean procedure for synthesis of benzo [c] acridine derivatives: reaction of N-arylidenenaphthalen-1-amine with 5, 5-dimethyl-1, 3-cyclohexadione in aqueous medium | |
JPS5817186B2 (ja) | 新規芳香族カルボン酸誘導体の製造方法 | |
JPH10265441A (ja) | 3−アセチル−シクロペンタンカルボン酸エステルの製造方法 | |
CA2591894C (en) | Process for producing 1-benzyl-4-[(5,6-dimethoxy-1-indanon2-yl)methyl] piperidine or its salt thereof via novel intermediate | |
JPH0140033B2 (ja) | ||
KR101475136B1 (ko) | 수용액 상에서의 2-(4-포르밀페닐)프로피온산의 친환경적인 제조방법 | |
JP2018062502A (ja) | 1−トリアゾール−2−ブタノール誘導体の製造方法 | |
EP1661894A1 (en) | Process for production of 4-aminotetrahydropyrans and salts thereof with acids, intermediates for the process, and process for production thereof | |
US6130330A (en) | Process for preparing macropolycyclic polyamines | |
EP2540717A1 (en) | Lamivudine oxalate and preparation method thereof | |
KR20140128318A (ko) | 1,4-보호된 9-하이드록시-5-옥소-1,4-디아자-스피로 [5.5] 운데칸의 입체선택적 합성 방법 | |
JPH06506920A (ja) | 1,3,4−トリ置換ピペリジン誘導体、その製造及び使用 | |
CN104520272B (zh) | 多奈哌齐衍生物 | |
JP3538630B2 (ja) | キノリン化合物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08710831 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12523341 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2008556217 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2008710831 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008710831 Country of ref document: EP |